Takeda announces new director assignments

OSAKA, Japan, June 26, 2024–(BUSINESS WIRE)–Takeda (TOKYO: 4502/NYSE: TAK) announced new directorships, determined at the Board of Directors meeting and the Audit and Oversight Committee meeting, following the 148th Ordinary Meeting of Shareholders, held in Osaka today.

Takeda’s Board of Directors has 11 members acting as external directors out of a total of 14 members, helping to ensure transparency and objectivity. One external director will continue to chair the Board of Directors. The Audit and Supervisory Committee, the Nomination Committee and the Compensation Committee will be composed solely of external directors including their Chairs.

Takeda places great emphasis on strong, independent governance and its Board of Directors helps ensure that all decisions and actions are in the best interests of global stakeholders and aligned with the company’s values. This robust corporate governance model has been and will continue to be essential to Takeda’s success.

The details of the new missions are as follows:

1. New assignment of directors who are not members of the audit and supervisory committee (as of June 26, 2024)

2. Directors who are members of the audit and supervisory committee (as of June 26, 2024)

3. New assignment of members of the Nominations Committee and the Remuneration Committee (effective June 26, 2024)

Nomination committee:
Masami Iijima (president), Steven Gillis, Emiko Higashi, Michel Orsinger, Jean-Luc Butel and Yoshiaki Fujimori
(Observer: Christophe Weber)

Compensation Committee:
Emiko Higashi (president), John Maraganore, Michel Orsinger and Kimberly A. Reed

The story continues

About Takeda
Takeda is focused on creating better health for people and a better future for the world. Our goal is to discover and deliver life-transforming treatments across our core therapeutic and business areas, including gastrointestinal and inflammatory diseases, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. . Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading Japan-based, values-based, R&D-driven biopharmaceutical company, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are anchored in the values ​​that have defined us for more than two centuries. For more information, visit www.takeda.com.

Important Notice
For the purposes of this notice, “press release” means this document, any oral presentations, any question and answer sessions and any written or oral materials discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) relating to this press release. This press release (including any oral briefing and any questions and answers relating thereto) is not intended to, and does not constitute, represent or form part of, an offer, invitation or solicitation an offer to purchase, acquire, subscribe for, exchange, sell or otherwise dispose of any securities or solicit a vote or approval in any jurisdiction. No shares or other securities are being offered to the public through this press release. No offering of securities will be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is provided (together with any additional information which may be provided to the recipient) on the condition that it is intended to be used by the recipient for informational purposes only (and not for the evaluation of a investment, acquisition, transfer or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly holds investments are separate entities. In this press release, “Takeda” is sometimes used for convenience when references are made to Takeda and its subsidiaries generally. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or those who work for them. These expressions are also used when it is not useful to identify the company or companies in question.

Forward-looking statements
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding the future business, future condition and results of operations of Takeda, including estimates, forecasts, objectives and plans for Takeda. Without limitation, forward-looking statements often include words such as “objectives,” “plans,” “believes,” “hopes,” “continues,” “expects,” “targets,” “intends,” “assures,” “will,” “may,” “should,” “would,” “could,” “anticipates,” “estimates,” “projects,” “forecasts,” “outlook” or similar expressions or the negative thereof. Such forward-looking statements are based on assumptions about many important factors, including the following, that could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global operations, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; challenges inherent in developing new products, including the uncertainty of clinical success and of decisions by regulatory authorities and the timing thereof; uncertainty of commercial success of new and existing products; manufacturing difficulties or delays; fluctuations in interest and foreign exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, such as the novel coronavirus pandemic; the success of our environmental sustainability efforts, in reducing our greenhouse gas emissions or achieving our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost savings, such as the integration of digital technologies, including artificial intelligence, into our business or other initiatives to restructure our operations, will result in the anticipated benefits; and other factors identified in Takeda’s most recent Annual Report on Form 20-F and in Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda undertakes no obligation to update any forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rules. Past performance is not an indicator of future results and Takeda’s results or statements in this press release may not be indicative and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240619545549/en/

Contacts

Media contacts:
Japanese media
Shoko Honda
[email protected]
+81 (0) 70-2687-3620

American and international media
Brendan Jennings
[email protected]
+81 (0) 80-2705-8259